Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly
Donald M. O’Rourke(University of Pennsylvania), Mark I. Greene(University of Pennsylvania), Acha Lee(University of Pennsylvania), James G. Davis(National Cancer Institute), Chih-Ching Kao(University of Pennsylvania), Chuan-Jin Wu(University of Pennsylvania), Eric JL Nute(National Cancer Institute), Xiaolan Qian(National Cancer Institute), Hongtao Zhang(Chinese Academy of Sciences), Ramachandran Murali(The Wistar Institute)
Cited by 53
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
|Neuro-Oncology|2018|314